3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms
5
Multiple Myeloma
3
Hematologic Neoplasms
3
Thyroid Cancer, Papillary
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Erdheim-Chester Disease
2
Carcinoma, Non-Small-Cell Lung
2
Xanthogranuloma, Juvenile
1
Thyroid Carcinoma, Anaplastic
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Glioma
1
Colorectal Neoplasms
1
Adenocarcinoma, Follicular
1
Interventions
entrectinib
2
atezolizumab
2
alectinib
2
venetoclax
1
pertuzumab
1
obinutuzumab
1
ibrutinib
1
etoposide phosphate
1
enzalutamide
1
cobimetinib
1
capmatinib
1
acalabrutinib
1
Vincristine
1
Vemurafenib
1
Trastuzumab
1
Specimen Handling
1
Rituximab
1
Radiotherapy
1
Prednisone
1
Positron-Emission Tomography
1
Nivolumab
1
Genetic Testing
1
Genetic Counseling
1
Follow-Up Studies
1
Etoposide
1
Doxorubicin
1
Cyclophosphamide
1
Chromatin Immunoprecipitation Sequencing
1
CA-4948
1
Biological Assay
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoproliferative Disorders
×
cobimetinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled